HeartFlow, Inc.

HeartFlow develops AI-driven software for coronary artery disease (CAD) diagnosis and management, transforming Coronary Computed Tomography Angiography (CCTA) imaging into personalized 3D cardiac models. The company's flagship platform, Heartflow One, combines CCTA imaging with proprietary FFR_CT (fractional flow reserve) analysis to assess coronary blood flow, identify plaque characteristics, and guide treatment decisions without invasive catheterization. The Heartflow One platform comprises three core analytical modules: Roadmap™ Analysis (CAD detection and anatomy assessment), FFR_CT Analysis (functional assessment of coronary stenosis to determine revascularization benefit), and Plaque Analysis (quantitative plaque characterization for risk stratification). Additionally, HeartFlow offers PCI Navigator for pre-procedural planning in percutaneous coronary intervention. The company serves over 1,800 healthcare institutions across the United States and internationally, with coverage reaching 99.5% of the US population. HeartFlow's technology is supported by over 600 peer-reviewed publications and has been endorsed by clinical statements from the American College of Cardiology and American Heart Association for personalized CAD management. The platform addresses significant diagnostic gaps in conventional methods (stress testing, PET, SPECT), which exhibit 20–30% false negatives and 55% false positives. HeartFlow provides institutional support beyond software, including clinical, operational, technical, and financial resources for CCTA program development and scaling.